Sequenced treatment alternatives to relieve adolescent depression (STAR-AD): a multicentre open-label randomized controlled trial protocol
Authors:
Open Access
- 27 October 2023
- journal article
- research article
- Published by Springer Nature in BMC Psychiatry
- Vol. 23 (1) , 1-11
Abstract
Background: Adolescent major depressive disorder (MDD) is a prevalent mental health problem with low treatment success rates. Whether fluoxetine or fluoxetine combined with cognitive-behavioural therapy (CBT) is the more effective initial treatment for adolescent MDD remains controversial, and few studies have investigated whether treatment switching or augmentation is preferred when the initial treatment is not working well. Methods: We developed a multicentre open-label Sequential Multiple Assignment Randomized Trial (SMART) design, consisting of two phases lasting 8 weeks each. In phase 1 (at baseline), patients will be recruited and grouped in fluoxetine group or fluoxetine combined with CBT group by patient self-selection. In phase 2 (after 8 weeks of treatment), the nonresponders will be randomly assigned to six groups, in which participants will switch to sertraline, vortioxetine, or duloxetine or added aripiprazole, olanzapine, or lithium carbonate to fluoxetine. After the full 16 weeks of treatment, we will assess the long-term sustainability of the treatment effects by evaluating participants during their subsequent naturalistic treatment. The primary outcome will be the response rate, determined by the Children’s Depression Rating Scale-Revised (CDRS-R). Secondary outcomes include the change in scores on the Beck Depression Inventory (BDI), the Screen for Child Anxiety-Related Emotional Disorders (SCARED) and the Safe Assessment. Discussion: The results from this study will aid clinicians in making informed treatment selection decisions for adolescents with MDD. Trial registration: This protocol was registered at ClinicalTrials.gov with Identifier: NCT05814640.Keywords
Funding Information
- Ministry of Science and Technology of the People´s Republic of China (2022ZD0212900)
This publication has 54 references indexed in Scilit:
- Validity of the 32-item Hypomania Checklist (HCL-32) in a clinical sample with mood disorders in ChinaBMC Psychiatry, 2011
- Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive DisorderJournal of Medicinal Chemistry, 2011
- Treatment of Resistant Depression in Adolescents (TORDIA): Week 24 OutcomesAmerican Journal of Psychiatry, 2010
- Reliability and validity of the screen for child anxiety related emotional disorders (SCARED) in Chinese childrenJournal of Anxiety Disorders, 2008
- Switching to Another SSRI or to Venlafaxine With or Without Cognitive Behavioral Therapy for Adolescents With SSRI-Resistant DepressionJAMA, 2008
- Effects of Psychotherapy for Depression in Children and Adolescents: What We Can (and Can't) Learn from Meta-Analysis and Component ProfilingJournal of the American Academy of Child & Adolescent Psychiatry, 2007
- The HCL-32: Towards a self-assessment tool for hypomanic symptoms in outpatientsJournal of Affective Disorders, 2005
- An experimental design for the development of adaptive treatment strategiesStatistics in Medicine, 2004
- A prospective study of depression and posttraumatic stress symptoms after a natural disaster: The 1989 Loma Prieta earthquake.Journal of Personality and Social Psychology, 1991
- A prospective study of depression and posttraumatic stress symptoms after a natural disaster: The 1989 Loma Prieta earthquake.Journal of Personality and Social Psychology, 1991